Our Newest Focus
Stock BioCurex (BOCX) has just announced it has entered into an
agreement with Abbot Laboratories under which Abbott obtains
worldwide, semi-exclusive rights to commercialize products using BioCurex's
RECAF technology. The agreement includes payment to BioCurex of up-front fees,
product development milestones and royalties on any product sales.
BioCurex
(BOCX)
???Patented
and proprietary technology that is leading the way in early detection and
effective treatment of cancer.???
'Results
have consistently proven that BioCurex successfully detects over 90% of all
cancers in blood or tissue samples ??“ levels significantly above any present
method.'
Press Release: Abott
and BioCurex Enter into Agreement for RECAF Cancer Technology...(BOCX)
An emerging cancer
biomarker, RECAF is found on malignant cells from a variety of cancer types and
may be useful in the development of new cancer tests.
Abbott and BioCurex
announced they have entered into a licensing agreement for BioCurex's RECAF(TM)
material and technology. The receptor for alpha-fetoprotein, RECAF has emerged
as a potential biomarker that may be useful in the development of new cancer
diagnostics tests. RECAF is found on malignant cells from a variety of cancer
cell types but is absent in most normal and benign cells. Preliminary studies
from the investigators at BioCurex have reported a high level of clinical
sensitivity and specificity for RECAF in many of the most common cancers,
including prostate, breast, colorectal, lung and others.
Under terms of the
agreement, Abbott obtains worldwide, semi-exclusive rights to commercialize
products using BioCurex's RECAF technology. The agreement includes payment to
BioCurex of up-front fees, product development milestones and royalties on any
product sales. Other terms of the agreement were not disclosed.
To view the Full Press Release
please visit
http://biz.yahoo.com/bw/050329/295396.html?.v=1
For the Full Profile on BOCX please visit
http://www.smallcapreview.com/bocx.htm
Approximate
Shares Outstanding: 28.9M
Market
Cap: $54.62M
Recent
Price: $1.89
BOCX Investment Highlights
- Results have consistently
proven that BioCurex successfully detects over 90% of all cancers in blood
or tissue samples ??“ levels significantly above any present method.'
- Reported positive detection results for an
additional type of cancer using its RECAF(tm) based blood test.
- Patented and proprietary,
innovative RECAF(tm) technology
- BOCX intends to license its technology to
companies involved in the manufacture, distribution and sale of cancer
diagnostic products.
- World renowned scientific team
- Experienced management team
- Favorable regulatory
environment and approval process
- Significant and growing market
with huge demand for the technology
- Widely accessible and easily
implemented by physicians
- Opportunity to reduce human
suffering and develop a profitable investment
Overview
BioCurex
(BOCX) BOCX is a leading edge
biotechnology company with proprietary and patented technologies in the areas of
cancer diagnosis, imaging and therapy.
BOCX is currently
developing and commercializing cancer diagnostic products based upon its
breakthrough RECAF cancer marker technology. The technology identifies a
cancer marker known as RECAF(tm), which is found on malignant cells from a
variety of cancer types but is absent in most normal or benign cells.
Results have consistently proven
that BioCurex successfully detects over 90% of all cancers in blood or tissue
samples ??“ levels significantly above any present method.
BOCX's mission is to
radically reduce human suffering through early cancer detection.
Products
HISTOLOGY AND CYTOLOGY
BioCurex??™s Histo-RECAF is a special cancer detection kit for tissues that
stains cancer cells brown, clearly distinguishing them from normal healthy
cells. Pathologists are able to easily identify cancer cells under a
conventional microscope for making a diagnosis.
LEUKEMIA Using
BOCX's technology, leukemia cells can be ???lit up??? so that only infected
blood cancer cells are isolated for targeted treatment. The clear implication of
the BioCurex technology is that physicians can detect any recurrence of the
blood cancer at a very early stage using equipment that is available today.
BLOOD AND SERUM TESTS
Using BOCX's technology, a basic blood test can determine if a patient has
cancer. Cancer cells shed the company's cancer marker RECAF into the blood
stream where it is detected. Because of its powerful detection capability and
simple execution, the Serum-RECAF will be a standardized blood test widely
available in any clinical laboratory. Physicians can then use Serum-RECAF as
frequently as required for both the initial screening of patients with symptoms,
and monitoring of those patients who have been previously treated for cancer.
TUMOR IMAGING Once
cancer has been diagnosed, it is crucial to determine its location and size.
Because the RECAF technology effectively detects cancer cells, cancer tissue can
be targeted with special compounds administered to the patient. Since only
cancer cells are selected, tumor locations can then be imaged using standard
equipment.
Recent News and Press
Releases
Abott
and BioCurex Enter into Agreement for RECAF Cancer Technology
BioCurex
Update
BioCurex's
RECAF Blood Test Outperforms PSA For Prostate Cancer Detection
WHISPERING
OAKS INTERNATIONAL INC Files SEC form 10QSB, Quarterly Report
BioCurex
Reports Positive Results on Colon Cancer Using its RECAF Blood Test -- Assay is
More Specific Than Currently Used Test
Disclaimer
SmallCapReview.com
feature stock reports are intended to be stock ideas, NOT recommendations.
Please do your own research before investing. It is crucial that you at least
look at current SEC filings and read the latest press releases. For
continuing coverage of BOCX, please sign up for our free newsletter,
SmallCapReview.com
News. Information contained in this report was extracted from current documents
filed with the SEC, the company web site and other publicly available sources
deemed reliable. For more information see our disclaimer section, a link of
which can be found on our web site. This document contains forward-looking
statements, particularly as related to the business plans of the Company, within
the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the
Securities Exchange Act of 1934, and are subject to the safe harbor created by
these sections. Actual results may differ materially from the Company's
expectations and estimates. The information provided in this report is not
intended for distribution to, or use by, any person or entity in any
jurisdiction or country where such distribution or use would be contrary to law
or regulation or which would subject us to any registration requirement within
such jurisdiction or country.
Copyright
SmallCapReview.com. All rights reserved. SmallCapReview.com is not a Registered
Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All
materials presented on our web site and individual reports released to the
public through this web site, e-mail or any other means of transmission are not
to be regarded as investment advice and are only for informative purposes.
Before making a purchase or sale of any securities featured on our web site
or mentioned in our reports, we strongly encourage and recommend consultation
with a registered securities representative. This is not to be construed as
a solicitation or recommendation to buy or sell securities. As with any stock,
companies we select to profile involve a degree of investment risk and
volatility. Particularly Small-Caps and OTC-BB stocks. All investors are
cautioned that they may lose all or a portion of their investment if they decide
to make a purchase in any of our profiled companies. Past performance of our
profiled stocks is not indicative of future results. The accuracy or
completeness of the information on our website or within our reports is only as
reliable as the sources they were obtained from. The profile and opinions
expressed herein are expressed as of the date the profile is posted on site and are
subject to change without notice. No investor should assume that reliance on the
views, opinions or recommendations contained herein will produce profitable
results. SmallCapReview.com may hold positions in securities mentioned herein,
and may make purchases or sales in such securities featured on our web site or
within our reports. In order to be in full compliance with the Securities Act
of 1933, Section 17(b), SmallCapReview.com will disclose in it's
disclaimer, what, if any compensation was received for our efforts in
researching, presenting and disseminating this information to our subscriber
database and featuring the report on the SmallCapReview.com website.
SmallCapReview.com has been compensated eight thousand five hundred dollars by a
third party for its efforts in presenting the BioCurex profile on its website
and distributing it to its database of subscribers. SmallCapReview.com may
decide to purchase or sell shares on a voluntary basis in the open market
before, during or after the profiling period of this report. Information
presented on our website and within our reports contain "forward looking
statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. Any statements that express or involve discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives, goals,
assumptions or future events or performance are not statements of historical
fact and may be "forward looking statements." Forward looking
statements are based on expectations, estimates and projections at the time the
statements are made that involve a number of risks and uncertainties which could
cause actual results or events to differ materially from those presently
anticipated. Forward looking statements in this action may be identified through
the use of words such as ???expects??™???, ???will,??? ???anticipates,???
???estimates, ???believes,??? or that by statements indicating certain actions
???may,??? ???could,??? or ???might??? occur.
THE
READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN
ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND
CARRIES A HIGH DEGREE OF RISK.
We
encourage our readers to invest carefully and read the investor information
available at the websites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its
website.
|
